OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TSTL58

Tristel PLC

Medical Equipment, Supplies & DistributionVerified

Tristel maintains a strong liquidity position with GBP 8.644 million in cash and equivalents, and a current ratio of 3.6, indicating a robust ability to cover short-term liabilities. The company's debt-to-equity ratio is 0.18, suggesting a conservative capital structure with limited leverage. Free cash flow is GBP 0.8 million, which is modest relative to operating cash flow of GBP 10.316 million, indicating some reinvestment in operations. Profitability metrics show a return on equity of 20.13% and a return on assets of 14.65%, both exceeding the industry median for medical equipment and supplies firms. Gross profit of GBP 37.459 million represents 80.6% of revenue, indicating strong pricing power or cost control. Operating income of GBP 8.397 million and net income of GBP 6.64 million suggest healthy margins, though the exact cohort median comparisons are not available in the input data. The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed in the input data. This lack of diversification may expose the company to regional economic or regulatory risks. No specific geographic revenue breakdown is provided, but the absence of multiple segments implies a single revenue stream. Tristel reported revenue of GBP 46.462 million in the latest period, with no prior-year data provided to assess growth. Analysts have set a mean price target of GBP 474.80, with a median of GBP 460.00, suggesting a generally positive outlook. The company's capital expenditure of GBP -1.982 million indicates some investment in operations, though the negative value may reflect a reduction in spending or a non-cash adjustment. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce credit risk, but the lack of geographic or segment diversification could increase exposure to sector-specific downturns. No dilution pressure is currently expected, and the number of shares outstanding is stable between basic and diluted shares. Recent events include analyst price targets and recommendations, with a mean recommendation of 1.60 (favoring buy) and three strong-buy ratings. No recent filings or transcripts are provided in the input data to detail operational or strategic developments.

30-day price · TSTL+4.00 (+1.0%)
Low$360.00High$420.84Close$385.00As of22 May, 00:00 UTC
Profile
CompanyTristel PLC
TickerTSTL.L
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Tristel PLC provides infection prevention and control solutions, primarily through the sale of medical equipment and supplies to healthcare institutions.

Classification. Tristel is classified in the Medical Equipment, Supplies & Distribution industry under the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Tristel maintains a strong liquidity position with GBP 8.644 million in cash and equivalents, and a current ratio of 3.6, indicating a robust ability to cover short-term liabilities. The company's debt-to-equity ratio is 0.18, suggesting a conservative capital structure with limited leverage. Free cash flow is GBP 0.8 million, which is modest relative to operating cash flow of GBP 10.316 million, indicating some reinvestment in operations. Profitability metrics show a return on equity of 20.13% and a return on assets of 14.65%, both exceeding the industry median for medical equipment and supplies firms. Gross profit of GBP 37.459 million represents 80.6% of revenue, indicating strong pricing power or cost control. Operating income of GBP 8.397 million and net income of GBP 6.64 million suggest healthy margins, though the exact cohort median comparisons are not available in the input data. The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed in the input data. This lack of diversification may expose the company to regional economic or regulatory risks. No specific geographic revenue breakdown is provided, but the absence of multiple segments implies a single revenue stream. Tristel reported revenue of GBP 46.462 million in the latest period, with no prior-year data provided to assess growth. Analysts have set a mean price target of GBP 474.80, with a median of GBP 460.00, suggesting a generally positive outlook. The company's capital expenditure of GBP -1.982 million indicates some investment in operations, though the negative value may reflect a reduction in spending or a non-cash adjustment. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce credit risk, but the lack of geographic or segment diversification could increase exposure to sector-specific downturns. No dilution pressure is currently expected, and the number of shares outstanding is stable between basic and diluted shares. Recent events include analyst price targets and recommendations, with a mean recommendation of 1.60 (favoring buy) and three strong-buy ratings. No recent filings or transcripts are provided in the input data to detail operational or strategic developments.
Key takeaways
  • Tristel has a strong liquidity position with a current ratio of 3.6 and GBP 8.644 million in cash and equivalents.
  • The company's return on equity of 20.13% and return on assets of 14.65% indicate strong profitability.
  • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • Analysts have a generally positive outlook, with a mean price target of GBP 474.80 and three strong-buy ratings.
  • The company has low debt and no immediate dilution or liquidity risks.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue$46.5M
Gross profit$37.5M
Operating income$8.4M
Net income$6.6M
R&D
SG&A
D&A
SBC
Operating cash flow$10.3M
CapEx-$2.0M
Free cash flow$800.0k
Total assets$45.3M
Total liabilities$12.3M
Total equity$33.0M
Cash & equivalents$8.6M
Long-term debt$5.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$33.0M
Net cash$2.8M
Current ratio3.6
Debt/Equity0.2
ROA14.6%
ROE20.1%
Cash conversion1.6%
CapEx/Revenue-4.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricTSTLActivity
Op margin18.1%3.9% medp25 -31.3% · p75 14.4%top quartile
Net margin14.3%2.4% medp25 -30.5% · p75 11.1%top quartile
Gross margin80.6%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.3%-4.8% medp25 -11.6% · p75 -2.4%above median
Debt / equity18.0%17.9% medp25 2.7% · p75 52.2%above median
Observations
IR observations
Mean price target474.80 GBP
Median price target460.00 GBP
High price target560.00 GBP
Low price target400.00 GBP
Mean recommendation1.60 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count1.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.17 GBP
Last actual EPS0.17 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-25 01:43 UTC#ed42b7c0
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 19:23 UTCJob: 07d27e46